Enlivex Therapeutics Ltd. 注册高达2333万股普通股供股东转售

投资观察
Apr 22

Enlivex Therapeutics Ltd. 近日向美国证券交易委员会提交文件,宣布注册最多23,333,333股普通股,用于由特定售股股东进行二次公开发售。

此次注册的股份将根据市场条件及其他因素,通过公开市场交易或与承销商协商的定价方式进行转售。该举措旨在为现有股东提供流动性,同时可能对公司股权结构产生影响。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10